Project Grant R21CA293614
Award Date 9/2/25
Completion Date 8/31/27
Dollars Obligated $444K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $306,265 federal Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on September 16, 2025, will fund the preclinical development of VAX024 - a novel, second-generation recombinant bacterial minicell-based targeted oncolytic in situ immunization (ISI) agent. VAX024 is designed to overcome limitations of current oncolytic viral therapies by leveraging the grantee's proprietary delivery technology to generate a sterile, user-friendly oncolytic...
- This federal Project Grant award of $640,522 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University supports research to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The project aims to carry out high-throughput screens of thousands of microbial macromolecules to identify those that directly modulate macrophages, with the goal of enhancing cancer immunotherapy...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Stanford University to investigate how the human gut microbiome can be modulated to enhance immune responses against cancer, with a focus on improving the efficacy of cancer immunotherapy treatments. The $179,988 award, which runs from January 1, 2025 to December 31, 2026, aims to identify bacterial genes and functions that can boost the body's immune response to immune...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) totaling $638,120 provides funding to The Trustees of Columbia University in the City of New York to conduct research aimed at improving the therapeutic efficacy and safety of microbial neoantigen vaccines for cancer treatment. The key objectives are to: 1) explore how bacterial localization within tumors affects immune responses and therapeutic outcomes, 2) investigate how bacterial...
- This federal Project Grant award of $846,982 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports a research project titled "Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy" at Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The research aims to advance the understanding of how the PD-1:SHP-2 axis in hematopoietic stem and progenitor cells impacts the differentiation and function of...
- This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), focuses on exploring the role of bacterial-derived small molecules in improving immunotherapy response rates and overall survival for non-small cell lung cancer patients. The $540,288 award to the University of Florida aims to test the central hypothesis that specific bacteria produce small molecules that can augment the efficacy and mitigate the toxicity of immune...
- This federal Project Grant award of $606,839.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to identify gut microbiota that actively deplete intestinal amino acids and evaluate how they affect the tumor microenvironment and cancer progression. The primary awardee is Weill Medical College of Cornell University, a leading academic medical institution with expertise in biomedical research and translational science. The project aims to...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- The federal Project Grant award of $397,772 was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research program) to Harvard T.H. Chan School of Public Health. The grant will fund the development of computational methods for profiling the cancer virome and analyzing microbial strain genetics from shotgun metagenomes and metatranscriptomes. This research aims to address key knowledge gaps in understanding the role of viruses and microbial strain variations...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the University of California, San Francisco (UCSF) to genetically engineer myeloid cells, including macrophages and dendritic cells, for the treatment of solid tumors. The $0.00 award, with a project period from August 1, 2025 to July 31, 2028, aims to apply advanced genetic engineering tools to reprogram myeloid cells and enhance their tumoricidal activities and resistance to...